🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

503 results for “Regeneron” Clear

  1. cemiplimab

    Regeneron UK Limited

    Non-small Cell Lung Cancer

    phase 3 small molecule active

    3 trials

  2. dupilumab

    Regeneron UK Limited

    Bullous Pemphigoid

    phase 3 small molecule completed

    1 trial

  3. dupilumab

    Regeneron UK Limited

    Moderate to Severe Atopic Hand and Foot Dermatitis

    phase 3 small molecule completed

    1 trial

  4. evinacumab

    Regeneron UK Limited

    Homozygous Familial Hypercholesterolemia

    phase 3 small molecule completed

    3 trials

  5. fianlimab

    Regeneron UK Limited

    Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  6. fianlimab

    Regeneron UK Limited

    Advanced Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  7. garetosmab

    Regeneron UK Limited

    Fibrodyplasia Ossificans Progressiva (FOP)

    phase 3 small molecule terminated

    1 trial

  8. garetosmab

    Regeneron UK Limited

    Fibrodysplasia Ossificans Progressiva (FOP)

    phase 3 small molecule active

    1 trial

  9. nexiguran ziclumeran

    Regeneron UK Limited

    Neuromuscular Disease

    phase 3 mab active

    1 trial

  10. rilonacept 160 mg

    Regeneron UK Limited

    Familial Cold Autoinflammatory Syndrome (FCAS)

    phase 3 small molecule completed

    1 trial

  11. sarilumab SAR153191 (REGN88)

    Regeneron UK Limited

    Rheumatoid Arthritis

    phase 3 small molecule completed

    6 trials

  12. ALN-ANG3

    Regeneron UK Limited

    Diabetic Kidney Disease (DKD)

    phase 2 small molecule active

    1 trial

  13. ALN-CFB

    Regeneron UK Limited

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 2 small molecule active

    1 trial

  14. ALN-CIDEB

    Regeneron UK Limited

    Metabolic Dysfunction-Associated Steatotic Liver Disease

    phase 2 small molecule active

    1 trial

  15. ALN-HSD

    Regeneron UK Limited

    Metabolic Dysfunction-Associated SteatoHepatitis (MASH)

    phase 2 small molecule active

    1 trial

  16. ALN-PNP

    Regeneron UK Limited

    Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

    phase 2 small molecule active

    1 trial

  17. ALN-PNP

    Regeneron UK Limited

    Healthy Volunteers

    phase 2 small molecule active

    1 trial

  18. ALN-SOD

    Regeneron UK Limited

    Amyotrophic Lateral Sclerosis (ALS)

    phase 2 small molecule active

    1 trial

  19. Aflibercept

    Regeneron UK Limited

    Radiation Retinopathy

    phase 2 small molecule active

    1 trial

  20. Aflibercept

    Regeneron UK Limited

    Proliferative Diabetic Retinopathy

    phase 2 small molecule completed

    1 trial

  21. Aflibercept

    Regeneron UK Limited

    Advanced Carcinoma

    phase 2 small molecule terminated

    1 trial

  22. Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)

    Regeneron UK Limited

    Pulmonary Diseases

    phase 2 small molecule completed

    1 trial

  23. Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)

    Regeneron UK Limited

    Neoplasms

    phase 2 small molecule completed

    1 trial

  24. Alirocumab

    Regeneron UK Limited

    Non Small Cell Lung Cancer

    phase 2 small molecule on hold

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources